Lexicon Pharmaceuticals, Inc. (LXRX): Price and Financial Metrics

Lexicon Pharmaceuticals, Inc. (LXRX): $1.15

0.09 (+8.49%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

F

Add LXRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#345 of 345

in industry

LXRX Price/Volume Stats

Current price $1.15 52-week high $3.79
Prev. close $1.06 52-week low $0.92
Day low $1.04 Volume 2,133,500
Day high $1.16 Avg. volume 1,696,991
50-day MA $1.14 Dividend yield N/A
200-day MA $1.99 Market Cap 281.66M

LXRX Stock Price Chart Interactive Chart >

LXRX POWR Grades

  • LXRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 28.06% of US stocks.
  • The strongest trend for LXRX is in Growth, which has been heading down over the past 177 days.
  • LXRX's current lowest rank is in the Quality metric (where it is better than 2.18% of US stocks).

LXRX Stock Summary

  • With a price/sales ratio of 465.86, LEXICON PHARMACEUTICALS INC has a higher such ratio than 99.15% of stocks in our set.
  • With a year-over-year growth in debt of 340.25%, LEXICON PHARMACEUTICALS INC's debt growth rate surpasses 96.89% of about US stocks.
  • Revenue growth over the past 12 months for LEXICON PHARMACEUTICALS INC comes in at 324.8%, a number that bests 97.98% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to LEXICON PHARMACEUTICALS INC are DZSI, TBIO, TARS, URGN, and SONO.
  • LXRX's SEC filings can be seen here. And to visit LEXICON PHARMACEUTICALS INC's official web site, go to www.lexpharma.com.

LXRX Valuation Summary

  • In comparison to the median Healthcare stock, LXRX's EV/EBIT ratio is 129.44% lower, now standing at -2.9.
  • LXRX's EV/EBIT ratio has moved up 0.3 over the prior 243 months.

Below are key valuation metrics over time for LXRX.

Stock Date P/S P/B P/E EV/EBIT
LXRX 2023-11-03 888.5 1.9 -2.8 -2.9
LXRX 2023-11-02 840.4 1.8 -2.6 -2.8
LXRX 2023-11-01 804.4 1.8 -2.5 -2.6
LXRX 2023-10-31 744.4 1.6 -2.3 -2.4
LXRX 2023-10-30 720.3 1.6 -2.2 -2.4
LXRX 2023-10-27 666.4 1.5 -2.1 -2.2

LXRX Growth Metrics

    Its 3 year revenue growth rate is now at -99.35%.
  • Its 5 year net cashflow from operations growth rate is now at 153.99%.
  • The year over year cash and equivalents growth rate now stands at -39.05%.
LXRX's revenue has moved down $321,948,000 over the prior 33 months.

The table below shows LXRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.125 -90.11 -97.061
2022-06-30 0.109 -87.821 -96.796
2022-03-31 0.308 -85.279 -90.276
2021-12-31 0.298 -87.017 -87.758
2021-09-30 0.483 -98.428 -67.642
2021-06-30 7.094 -121.656 38.083

LXRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LXRX has a Quality Grade of D, ranking ahead of 14.8% of graded US stocks.
  • LXRX's asset turnover comes in at 0.038 -- ranking 340th of 681 Pharmaceutical Products stocks.
  • SEEL, AVEO, and OTLK are the stocks whose asset turnover ratios are most correlated with LXRX.

The table below shows LXRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.038 0.911 2.792
2021-03-31 0.071 0.915 -0.037
2020-12-31 0.089 0.920 -0.233
2020-09-30 0.101 0.917 -0.269
2020-06-30 0.824 0.992 0.131
2020-03-31 0.875 0.990 0.239

LXRX Price Target

For more insight on analysts targets of LXRX, see our LXRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.50 Average Broker Recommendation 1.67 (Moderate Buy)

Lexicon Pharmaceuticals, Inc. (LXRX) Company Bio


Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.


LXRX Latest News Stream


Event/Time News Detail
Loading, please wait...

LXRX Latest Social Stream


Loading social stream, please wait...

View Full LXRX Social Stream

Latest LXRX News From Around the Web

Below are the latest news stories about LEXICON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LXRX as an investment opportunity.

Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2023: 35th Annual Piper Sandler Healthcare Conference6th Annual Evercore ISI HealthCONx Conference Lonnel Coats, Lexicon’s chief executive officer, Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Cr

Yahoo | November 22, 2023

Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc

Recent insider trading activity has caught the attention of market analysts and investors alike, as Director Philippe Amouyal has made a significant purchase of shares in Lexicon Pharmaceuticals Inc (NASDAQ:LXRX).

Yahoo | November 15, 2023

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high risk for cardiovascular events INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today

Yahoo | November 12, 2023

Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place November 14-16, 2023. Jeff Wade, Lexicon’s president and chief financial officer, and Tom Garner, Lexicon’s senior vice president and chief commercial officer, will make a company presentation at 5:00 pm GMT / 12:00 pm EST on Wednesday, November 15th. A simultaneous webcast of the presentation will be ava

Yahoo | November 10, 2023

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript November 8, 2023 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.22. Operator: Good day and welcome to the Lexicon Pharmaceuticals’ Third Quarter 2023 Financial Results Conference Call. Today all participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, […]

Yahoo | November 10, 2023

Read More 'LXRX' Stories Here

LXRX Price Returns

1-mo -22.30%
3-mo -29.88%
6-mo -60.75%
1-year -49.12%
3-year -27.22%
5-year N/A
YTD -39.79%
2022 -51.52%
2021 15.20%
2020 -17.59%
2019 -37.50%
2018 -32.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!